DCM
CNTX icon

Driehaus Capital Management’s Context Therapeutics CNTX Stock Holding History

Driehaus Capital Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,258,065
Closed -$4.53M – 398
2024
Q2 		$4.53M Buy
+2,258,065
New +$3.89M 0.04% 267

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Driehaus Capital Management's CNTX Position: Q3 2024 in Review

Driehaus Capital Management sold out of Context Therapeutics (CNTX) in Q3 2024, closing a stake of 2,258,065 shares — an estimated $4.53M sold.

Driehaus Capital Management first reported a position in CNTX in Q2 2024 and held it in 1 quarter. The position peaked at $4.53M in Q2 2024. 42 funds tracked by Wall St. Rank hold CNTX as of Q3 2024.

  • Driehaus Capital Management reported no remaining Context Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Driehaus Capital Management sold 2,258,065 Context Therapeutics shares in Q3 2024, an estimated $4.53M.
  • Driehaus Capital Management first reported a position in Context Therapeutics in Q2 2024 and held it in 1 quarter.
  • Driehaus Capital Management's Context Therapeutics position peaked at $4.53M in Q2 2024.
  • 42 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2024.

Based on Driehaus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.